Last reviewed · How we verify
LATANOPROST 0.005% EYEDROPS
Latanoprost 0.005% eyedrops, marketed by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, holds a position in the glaucoma treatment market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and market presence, supported by its current marketing status. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | LATANOPROST 0.005% EYEDROPS |
|---|---|
| Also known as | Latanoprost 0.005% eyedrops generic drug |
| Sponsor | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension (PHASE2, PHASE3)
- Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment
- Rocklatan vs Latanoprost Post-DSLT (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Optic Nerve Head Strain in Non-glaucoma Subjects (EARLY_PHASE1)
- Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction (PHASE3)
- Next Generation Rocklatan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: